litlas
Log inCreate account

C.E.M. Griffiths

Active 1985–2025

Also published as
C E M Griffiths
329
Papers
58,282
Citations
129
h-index
321
i10-index

Citations

Citations per year for C.E.M. Griffiths1964: 4 citations1985: 1 citations1986: 2 citations1987: 6 citations1988: 9 citations1989: 28 citations1990: 52 citations1991: 77 citations1992: 62 citations1993: 101 citations1994: 89 citations1995: 68 citations1996: 87 citations1997: 82 citations1998: 86 citations1999: 67 citations2000: 120 citations2001: 156 citations2002: 111 citations2003: 168 citations2004: 218 citations2005: 272 citations2006: 269 citations2007: 304 citations2008: 254 citations2009: 328 citations2010: 312 citations2011: 325 citations2012: 293 citations2013: 341 citations2014: 298 citations2015: 372 citations2016: 402 citations2017: 530 citations2018: 490 citations2019: 1,568 citations2020: 1,696 citations2021: 1,739 citations2022: 1,541 citations2023: 1,277 citations2024: 2,107 citations2025: 892 citations2026: 19 citations1965–1984: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,886 citing papers, 20.9% of this breakdownUnited Kingdom: 1,716 citing papers, 9.2% of this breakdownChina: 1,435 citing papers, 7.7% of this breakdownGermany: 1,366 citing papers, 7.3% of this breakdownItaly: 1,015 citing papers, 5.4% of this breakdownCanada: 792 citing papers, 4.3% of this breakdownFrance: 699 citing papers, 3.8% of this breakdownJapan: 592 citing papers, 3.2% of this breakdownSpain: 559 citing papers, 3% of this breakdownSwitzerland: 544 citing papers, 2.9% of this breakdownNetherlands: 532 citing papers, 2.9% of this breakdownDenmark: 368 citing papers, 2% of this breakdown
0%20.9%Other 27.4%

Institutions

Fields

  • Medicine42.8%
  • Immunology and Microbiology38.4%
  • Biochemistry, Genetics and Molecular Biology10.2%
  • Pharmacology, Toxicology and Pharmaceutics1.9%
  • Neuroscience1.2%
  • Dentistry0.9%
  • Other4.6%

Topics

  • Psoriasis: Treatment and Pathogenesis15.1%
  • Dermatology and Skin Diseases10.1%
  • Spondyloarthritis Studies and Treatments5.7%
  • Asthma and respiratory diseases2.5%
  • Skin Protection and Aging2.4%
  • Rheumatoid Arthritis Research and Therapies2.4%
  • Other61.8%

Coauthors

All papers

Open in search
  1. Psoriasis

    Authors: C.E.M. Griffiths, April W. Armstrong, Jóhann E. Guðjónsson, Jonathan N W N Barker - The Lancet 2021 cited by 2,243

  2. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study

    Authors: Rosa Parisi, Ireny Iskandar, Evangelos Kontopantelis, Matthias Augustin, C.E.M. Griffiths, Darren M. Ashcroft - BMJ 2020 cited by 1,146

  3. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

    Authors: Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham, Jennifer Clay Cather, Jamie Weisman, David M. Pariser, Eric L. Simpson, Kim Papp, Hyuck-Ki Hong, Diana Rubel, Peter Foley, Errol P. Prens, C.E.M. Griffiths, Takafumi Etoh, Pedro Herranz, Ramón M. Pujol, Jacek C. Szepietowski, Karel Ettler, Lajos Kemény, Xiaoping Zhu, Bolanle Akinlade, Thomas Hultsch, Vera Mastey, Abhijit Gadkari, Laurent Eckert, Nikhil Amin, Neil M.H. Graham, Gianluca Pirozzi, Neil Stahl, George D. Yancopoulos, Brad Shumel - The Lancet 2017 cited by 1,243

  4. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

    Authors: Rosa Parisi, Deborah Symmons, C.E.M. Griffiths, Darren M. Ashcroft - Journal of Investigative Dermatology 2012 cited by 2,575

  5. Pathogenesis and clinical features of psoriasis

    Authors: C.E.M. Griffiths, Jonathan NWN Barker - The Lancet 2007 cited by 2,116

  6. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

    Authors: Richard G. Langley, Boni E. Elewski, Mark Lebwohl, Kristian Reich, C.E.M. Griffiths, Kim Papp, L. Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson, Enrique Rivas, Tsen‐Fang Tsai, Norman Wasel, Stephen K. Tyring, Thomas Salko, Isabelle Hampele, Marianne Notter, Alexander Karpov, Silvia Helou, C. Papavassilis - New England Journal of Medicine 2014 cited by 1,964

  7. Psoriasis Prevalence in Adults in the United States

    Authors: April W. Armstrong, Manan D. Mehta, Clayton W. Schupp, George Gondo, Stacie Bell, C.E.M. Griffiths - JAMA Dermatology 2021 cited by 460

  8. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

    Authors: Andrew Blauvelt, Kim Papp, C.E.M. Griffiths, B. Randazzo, Yasmine Wasfi, Yaung‐Kaung Shen, Shu Li, Alexa B. Kimball - Journal of the American Academy of Dermatology 2017 cited by 860

  9. Psoriasis: epidemiology, clinical features, and quality of life

    Authors: Richard G. Langley, G G Krueger, C E M Griffiths - Annals of the Rheumatic Diseases 2005 cited by 1,107

  10. Academia Europaea Position Paper on Translational Medicine: The Cycle Model for Translating Scientific Results into Community Benefits

    Authors: Péter Hegyi, Ole H. Petersen, Stephen T. Holgate, Bálint Erőss, András Garami, Zsolt Szakács, Dalma Dobszai, Márta Balaskó, Lajos Kemény, Shuang Peng, João Monteiro, András Varró, Tara Lamont, Jeffrey Laurence, Zoe Gray, Andrew Pickles, Garret A. FitzGerald, C.E.M. Griffiths, Jacek Jassem, Dmitri A. Rusakov, Alexei Verkhratsky, Andrea Szentesi - Journal of Clinical Medicine 2020 cited by 216

  11. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

    Authors: Kim Papp, Kristian Reich, Craig L. Leonardi, Leon Kircik, Sergio Chimenti, Richard G. Langley, ChiaChi Hu, Randall M. Stevens, Robert M. Day, Kenneth B. Gordon, Neil J. Korman, C.E.M. Griffiths - Journal of the American Academy of Dermatology 2015 cited by 669

  12. Clinical Applications of Machine Learning Algorithms: Beyond the Black Box

    Authors: David M. Watson, Jenny Krutzinna, Ian N Bruce, C.E.M. Griffiths, Iain B. McInnes, Michael R. Barnes, Luciano Floridi - BMJ 2019 cited by 442

  13. Inflammaging and the Skin

    Authors: Suzanne M. Pilkington, Silvia Bulfone‐Paus, C.E.M. Griffiths, Rachel Watson - Journal of Investigative Dermatology 2021 cited by 198

  14. Psoriasis and Treatment: Past, Present and Future Aspects

    Authors: Claire Reid, C.E.M. Griffiths - Acta Dermato Venereologica 2020 cited by 217

  15. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis

    Authors: Zenas Z N Yiu, G Becher, Brian Kirby, Philip Laws, Nick J. Reynolds, Catherine Smith, Richard B. Warren, C.E.M. Griffiths, BADBIR Study Group, Fiona Browne, Ian Evans, Elise Kleyn, Linda Lawson, Kathleen McElhone, Teena Mackenzie, Tess McPherson, Ruth Murphy, Caroline Owen, Eleanor Pearson, Josh Richards, Mark Lunt, A. David Burden, Oras Alabas, Simon Morrison, Shernaz Walton, Anthony Bewley, Shehnaz Ahmed, L. Jones, Charlotte Symons, Jonathan Barker, Philip Hampton - JAMA Dermatology 2022 cited by 144

  16. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity

    Authors: Lam C. Tsoi, Sarah L. Spain, Jo Knight, Eva Ellinghaus, Philip E. Stuart, Francesca Capon, Jun Ding, Yanming Li, Trilokraj Tejasvi, Jóhann E. Guðjónsson, Hyun Min Kang, Michael H. Allen, Ross McManus, Giuseppe Novelli, Lena Samuelsson, Joost Schalkwijk, Mona Ståhle, A. David Burden, Catherine Smith, Michael J. Cork, Xavier Estivill, A. Bowcock, Gerald G. Krueger, Wolfgang Weger, Jane Worthington, Rachid Tazi‐Ahnini, Frank O. Nestlé, Adrian Hayday, Per Hoffmann, Juliane Winkelmann, Cisca Wijmenga, Cordelia Langford, Sarah Edkins, Robert Andrews, Hannah Blackburn, Amy Strange, Gavin Band, Richard D. Pearson, Damjan Vukcevic, Chris C. A. Spencer, Panos Deloukas, Ulrich Mrowietz, Stefan Schreiber, Stephan Weidinger, Sulev Kõks, Külli Kingo, Tõnu Esko, Andres Metspalu, Henry W. Lim, John J. Voorhees, Michael Weichenthal, H.‐Erich Wichmann, Vinod Chandran, Cheryl F. Rosen, Proton Rahman, Dafna D. Gladman, C.E.M. Griffiths, André Reis, Juha Kere, Rajan P. Nair, André Franke, Jonathan N W N Barker, Gonçalo R. Abecasis, James T Elder, Richard C. Trembath - Nature Genetics 2012 cited by 1,047

  17. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

    Authors: C.E.M. Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, C. Paul, Alan Menter, Gregory S. Cameron, J. Erickson, Lu Zhang, Roberta J. Secrest, Susan Ball, Daniel Braun, Olawale Osuntokun, Michael Heffernan, Brian J. Nickoloff, Kim Papp - The Lancet 2015 cited by 831

  18. Definition of treatment goals for moderate to severe psoriasis: a European consensus

    Authors: Ulrich Mrowietz, Knud Kragballe, Kristian Reich, Phyllis I. Spuls, C.E.M. Griffiths, Alexander Nast, J Franke, C. Antoniou, Petr Arenberger, Flora Balieva, Matilda Bylaitė, Osvaldo Correia, E. Daudén, Paolo Gisondi, Lars Iversen, Lajos Kemény, M. Lahfa, Tamar Nijsten, Tapio Rantanen, Adam Reich, T. Rosenbach, Siegfried Segaert, Catherine Smith, T. Talme, Beatrix Volc‐Platzer, Nikhil Yawalkar - Archives of Dermatological Research 2010 cited by 886

  19. Clinical and genetic differences between pustular psoriasis subtypes

    Authors: Sophie Twelves, Alshimaa Mostafa, Nick Dand, Elias Burri, Katalin Farkas, Rosemary Wilson, Hywel Cooper, Alan D. Irvine, Hazel H. Oon, Külli Kingo, Sulev Kõks, Ulrich Mrowietz, L. Puig, Nick J. Reynolds, Eugene Tan, Adrian Tanew, Kaspar Torz, Hannes Trattner, Mark C. Valentine, Shyamal Wahie, Richard B. Warren, Andrew Wright, Zsuzsanna Bata‐Csörgõ, Márta Széll, C.E.M. Griffiths, A. David Burden, Siew Eng Choon, Catherine Smith, Jonathan N. Barker, Alexander A. Navarini, Francesca Capon - Journal of Allergy and Clinical Immunology 2018 cited by 268

  20. Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender*

    Authors: Ireny Iskandar, Rosa Parisi, C.E.M. Griffiths, Darren M. Ashcroft, the Global Psoriasis Atlas - British Journal of Dermatology 2020 cited by 176

  21. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council

    Authors: Bruce Strober, Caitriona Ryan, Peter van de Kerkhof, Joelle van der Walt, Alexa B. Kimball, Jonathan Barker, Andrew Blauvelt, Marc Bourcier, André Vicente Esteves de Carvalho, Arnon D. Cohen, Peter Foley, Colby Evans, Paolo Gisondi, C.E.M. Griffiths, Mahira Hamdy El-Sayed, Cristina Eschevarria, A.Y. Finlay, Robert E. Kalb, Craig L. Leonardi, C. Lynde, Ruth Murphy, Masamoto Murakami, Yukari Okubo, Errol P. Prens, L. Puig, Marieke M.B. Seyger, Lone Skov, Tadashi Terui, Fernando Valenzuela, Nicole L. Ward, Jashin J. Wu, Min Zheng - Journal of the American Academy of Dermatology 2019 cited by 243

  22. Five‐year maintenance of clinical response and health‐related quality of life improvements in patients with moderate‐to‐severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2*

    Authors: Kristian Reich, Kenneth B. Gordon, Bruce Strober, April W. Armstrong, Megan Miller, Yaung‐Kaung Shen, Yin You, Chenglong Han, Ya‐Wen Yang, Peter Foley, C.E.M. Griffiths - British Journal of Dermatology 2021 cited by 81

  23. Age-Associated Skin Conditions and Diseases: Current Perspectives and Future Options

    Authors: Ulrike Blume‐Peytavi, Jan Kottner, Wolfram Sterry, Michael W. Hodin, Tamara Griffiths, Rachel Watson, Roderick J. Hay, C.E.M. Griffiths - The Gerontologist 2016 cited by 222

  24. Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial

    Authors: Richard B. Warren, Adam Reich, Andrzej Kaszuba, Waldemar Placek, C.E.M. Griffiths, Jihao Zhou, Bruce Randazzo, Paul F. Lizzul, Jóhann E. Guðjónsson - British Journal of Dermatology 2023 cited by 53